Faron Pharmaceuticals Oyj | Key People and Executives
Frank Murdoch Armstrong
Non-Executive Chairman
Markku Tapani Jalkanen
Chief Executive Officer & Executive Director
Yrjö Erik Kristian Wichmann
Chief Financial Officer & Executive Director
John Poulos
Non-Executive Director
Greg B. Brown
Non-Executive Director
Matti Esa Manner
Non-Executive Vice Chairman
Huai Zheng Peng
Non-Executive Director
Leopoldo Giampaolo Zambeletti
Non-Executive Director
J. Kenneth Charles Knowles
Non-Executive Director
Frank Murdoch Armstrong
Non-Executive Chairman
Markku Tapani Jalkanen
Chief Executive Officer & Executive Director
Mikael Maksimow
Vice President-Operations
Yrjö Erik Kristian Wichmann
Chief Financial Officer & Executive Director
Jami Mandelin
Research Director
Matti Karvonen
Chief Medical Officer & VP-Drug Development
Juho Markku Jalkanen
Chief Development Officer
Juhana Heinonen
Chief Commercial Officer
John Poulos
Non-Executive Director
Greg B. Brown
Non-Executive Director
Matti Esa Manner
Non-Executive Vice Chairman
Huai Zheng Peng
Non-Executive Director
Leopoldo Giampaolo Zambeletti
Non-Executive Director
J. Kenneth Charles Knowles
Non-Executive Director
| Address |
Joukahaisenkatu 6
Turku FP 20520
Finland
|
|
Employees
|
- |
| Website |
http://www.faron.com |
| Updated |
07/08/2019 |
| Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development. The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage. It operates through the Traumakine and Clevegen brands for acute respiratory distress syndrome, and for pre-clinical anti-Clever-1 antibody respectively. |
